Monday, 18 November 2013
Medishafted!
Shame that Mediwatch as a company turned out to be a failure......directors did okay though,which is the main thing!!!!!!!!!!!!!!
Tuesday, 5 November 2013
Urology Nurses and Associates Week
Urology nurses care for patients across the lifespan, providing guidance and treatment for a variety of urologic diseases and concerns. They work in all health care settings and specialize in such areas as continence care, male/female sexual dysfunction, infertility, oncology, surgery, cystoscopy, and urodynamics.
To recognize how valuable urologic nurses and associates are to the health care system and to their patients, the Society of Urologic Nurses and Associates (SUNA) has established Urology Nurses and Associates Week.
Sponsored by SUNA, Urology Nurses and Associates Week will be celebrated November 1-7 each year. During this special week, employers, patients and others can pay tribute to urologic health care professionals. Urology nurses and associates can also raise awareness of the specialty during this celebratory week.
Urology Nurses and Associates Week began in 2006 and was a highlight of SUNA’s 2006 Annual Conference in Kansas City, MO.
To recognize how valuable urologic nurses and associates are to the health care system and to their patients, the Society of Urologic Nurses and Associates (SUNA) has established Urology Nurses and Associates Week.
Sponsored by SUNA, Urology Nurses and Associates Week will be celebrated November 1-7 each year. During this special week, employers, patients and others can pay tribute to urologic health care professionals. Urology nurses and associates can also raise awareness of the specialty during this celebratory week.
Urology Nurses and Associates Week began in 2006 and was a highlight of SUNA’s 2006 Annual Conference in Kansas City, MO.
Saturday, 2 November 2013
Cerne Abbas Giant-moustache for Movember
A huge grass moustache has been added
to the UK's largest chalk hill figure.
The Cerne Abbas Giant in Dorset is sporting facial "hair" in support of Movember, which raises awareness of prostate and testicular cancer.
The National Trust's Rob Rhodes said: "It's all a bit of fun to highlight an important subject so we were happy to give our support and join in the fun."
He said the moustache would remain for one day, and that there would be no damage to the giant.
"I am sure the giant would approve," he added.
The ancient 180ft (55m) tall giant's new moustache is 36ft (11m) by 9ft (2.7m).
A spokesman at British Seed Houses, which grew the whiskers, said it gave him a "rakish" appearance.
Local folklore describes the club-wielding figure, which dates back to at least 1694, as a symbol of spirituality and fertility.
The giant attracted attention in the summer of 2007 when a temporary chalk figure of Homer Simpson was drawn next to it, to promote The Simpsons Movie.
Money is raised for Movember during November each year by men growing moustaches to support health programmes that combat prostate and testicular cancer, and mental health challenges.
LATEST NEWS AND FUTURE EVENTS
Latest News/Website Updates
Urology Times-November Issue
Renal & Urology News-November Issue
Oct 18 (Reuters) - Mediwatch PLC : * Response to increase in share price * Mediwatch confirms that it has received an initial approach from laborie
Mediwatch Positions/Jobs
Future Events Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later
2013 LUGPA Annual Meeting (Chicago) November 7-9, 2013Mediwatch/Distributor Training Courses
Urodynamics Workshop WPB--- 23,24 Mar 2013
ARM Workshop Boston 31 May 2013
Urodynamics Workshop WPB 9,10 Nov 2013
Newsletters
Mediwatch Newsletter 2013 Q3
Mediwatch Newsletter 2013 Q2
Mediwatch Newsletter 2012 Q1
Mediwatch Newsletter 2011 Q4
STUFF THAT MAYBE DID BUT NOW DOESN'T FIT IN WITH THE TITLE...
Saturday, 26 October 2013
Movember's new branding for 2013 event
The Movember men’s health initiative has launched new branding for this year’s event.
Movember encourages men to grow moustaches during November to raise awareness of, and funds for, prostate and testicular cancer.
The branding, which is refreshed each year, is created by Melbourne-based consultancy Urchin Associates.
Last year’s look was based on the idea of a traditional father-and-son run business; while this year’s branding has a monochrome palette, with a rebellious aesthetic based on a campaign message ‘if you don’t like our moustaches we don’t like your laws’.
The main Movember word-mark has a hand-drawn brushstroke look, and is always capitalised; while secondary text uses capitalised stencil-like typography.
Snake and wolf graphics are used across the branding, with a two-headed snake forming a line above the logo on a number of applications and a howling wolf seen with lightening flashes.
Movember encourages men to grow moustaches during November to raise awareness of, and funds for, prostate and testicular cancer.
The branding, which is refreshed each year, is created by Melbourne-based consultancy Urchin Associates.
Last year’s look was based on the idea of a traditional father-and-son run business; while this year’s branding has a monochrome palette, with a rebellious aesthetic based on a campaign message ‘if you don’t like our moustaches we don’t like your laws’.
The main Movember word-mark has a hand-drawn brushstroke look, and is always capitalised; while secondary text uses capitalised stencil-like typography.
Snake and wolf graphics are used across the branding, with a two-headed snake forming a line above the logo on a number of applications and a howling wolf seen with lightening flashes.
Thursday, 24 October 2013
Movember-bits and bobs
The Mr Mo book can be bought from Amazon, while there are more details about Movemeber here. Metro is also giving away 100 limited-edition printed copies of the new book. For a chance to win one, go to metro.co.uk/madeforthecity
GENERAL,UROLOGY and CHARITY WEBSITES (Updated-24th October 2013)
This is a copy of useful websites found in the main information pages under April 2009....
Posted again to remind me to add/remove any as required and update said April 2009 pages too! (added CANSA-South Africa)
GENERAL/UROLOGY MEDICAL
WEBSITES
CANSA-South Africa
OncLive
PULSE-General Medical Information/News
Prostate Conditions Education Council (PCEC)-USA
British Association of Urological Nurses(BAUN)
EUROCARE
URO TODAY
UROLOGY TIMES
American Urological Association
EUROPEAN ASSOCIATION OF UROLOGY
NHS-CHOICES
NICE-INDEPENDENT ADVISORY GROUP (UK)
PATIENT UK
MEDICAL NEWS TODAY (UK with global news)
Scottish Practice Nurses Association
MEDICAL DAILY
University of Florida Shands Cancer Center
European Hospital
UROLOGY,CANCER AND PROSTATE
CANCER SPECIFIC CHARITY WEBSITES
UK
The Urology Foundation (UK)
The Graham Fulford Charitable Trust (UK)
Friends of Prostate Sufferers (FOPS) (UK)
PCaSO-Prostate Cancer Network (UK)
Prostaid (UK)
UCARE-UK
THE PROSTATE SCREENING TRUST
PROSTATE SCOTLAND
BRISTOL UROLOGICAL INSTITUTE
PROSTATE CANCER UK
Prostate Cancer UK-Youtube Channel
PROSTATE CANCER SUPPORT ASSOCIATION (UK)
CANCER RESEARCH UK
CANCERBACKUP/MACMILLAN (UK)
The Cystitis and Overactive Bladder Foundation (UK)
The Bladder and Bowel Foundation (UK)
The X Foundation (Raising money for the Prostate Cancer Research Foundation"
ROW
Prostate Cancer InfoLink
The Prostate Cancer Foundation of Australia
The Cancer Society of New Zealand
The Prostate Cancer Foundation-USA
American Cancer Society
Canadian Prostate Cancer Network
CANADIAN CANCER SOCIETY
WORLD CANCER RESEARCH FUND
ZERO (USA)
Posted again to remind me to add/remove any as required and update said April 2009 pages too! (added CANSA-South Africa)
GENERAL/UROLOGY MEDICAL
WEBSITES
CANSA-South Africa
OncLive
PULSE-General Medical Information/News
Prostate Conditions Education Council (PCEC)-USA
British Association of Urological Nurses(BAUN)
EUROCARE
URO TODAY
UROLOGY TIMES
American Urological Association
EUROPEAN ASSOCIATION OF UROLOGY
NHS-CHOICES
NICE-INDEPENDENT ADVISORY GROUP (UK)
PATIENT UK
MEDICAL NEWS TODAY (UK with global news)
Scottish Practice Nurses Association
MEDICAL DAILY
University of Florida Shands Cancer Center
European Hospital
UROLOGY,CANCER AND PROSTATE
CANCER SPECIFIC CHARITY WEBSITES
UK
The Urology Foundation (UK)
The Graham Fulford Charitable Trust (UK)
Friends of Prostate Sufferers (FOPS) (UK)
PCaSO-Prostate Cancer Network (UK)
Prostaid (UK)
UCARE-UK
THE PROSTATE SCREENING TRUST
PROSTATE SCOTLAND
BRISTOL UROLOGICAL INSTITUTE
PROSTATE CANCER UK
Prostate Cancer UK-Youtube Channel
PROSTATE CANCER SUPPORT ASSOCIATION (UK)
CANCER RESEARCH UK
CANCERBACKUP/MACMILLAN (UK)
The Cystitis and Overactive Bladder Foundation (UK)
The Bladder and Bowel Foundation (UK)
The X Foundation (Raising money for the Prostate Cancer Research Foundation"
ROW
Prostate Cancer InfoLink
The Prostate Cancer Foundation of Australia
The Cancer Society of New Zealand
The Prostate Cancer Foundation-USA
American Cancer Society
Canadian Prostate Cancer Network
CANADIAN CANCER SOCIETY
WORLD CANCER RESEARCH FUND
ZERO (USA)
Tuesday, 22 October 2013
Canada-PCC New Recommendations
4th September 2013
TORONTO: New recommendations released today by Prostate Cancer Canada (PCC) will empower Canadian males to take a more active role in monitoring their number one cancer risk: prostate cancer. A recent nationwide poll showed that while 87% of Canadian men aged 35+ fear prostate cancer, less than half anticipate being tested in the next 12 months – even though early diagnosis can increase the odds of survival.
“Prostate Cancer Canada recognizes that men need to be better informed about prostate testing, particularly the Prostate Specific Antigen (PSA) blood test,” says Dr. Stuart Edmonds, VP, Research, Health Promotion & Survivorship, Prostate Cancer Canada. “To address this confusion, we conducted an extensive review of the evidence and from this developed our primary recommendation: Men should get a baseline PSA test in their 40s instead of waiting until their 50s.”
“PSA levels can vary between individuals so a test in the early 40’s can provide a baseline and allow us to better tailor clinical follow-up,” says Prostate Cancer Canada spokesperson Dr. Rajiv Singal, Urologist at Toronto East General Hospital and Assistant Professor at the University of Toronto. “The PSA is an important marker for a disease in which symptoms are not always present.”
PCC also recommends the decision to end PSA testing should be based on individual risk, rather than an arbitrary cut-off such as age 70. “Men are living longer and their lives should not be cut short or diminished by prostate cancer,” says Dr. Edmonds. “The decision to end testing should be a shared decision determined by a man and his primary care provider.”
“Some men are at increased risk because of ethnicity (Black African or Black Caribbean descent), a family history of prostate cancer, or age,” says Dr. Singal. “Men at high risk should talk to their primary care provider even earlier than their 40s. However, in my 18 years of practice, the majority of aggressive cancers have been found in men with seemingly no risk factors – underscoring the importance of baseline testing.”
More from link below
TORONTO: New recommendations released today by Prostate Cancer Canada (PCC) will empower Canadian males to take a more active role in monitoring their number one cancer risk: prostate cancer. A recent nationwide poll showed that while 87% of Canadian men aged 35+ fear prostate cancer, less than half anticipate being tested in the next 12 months – even though early diagnosis can increase the odds of survival.
“Prostate Cancer Canada recognizes that men need to be better informed about prostate testing, particularly the Prostate Specific Antigen (PSA) blood test,” says Dr. Stuart Edmonds, VP, Research, Health Promotion & Survivorship, Prostate Cancer Canada. “To address this confusion, we conducted an extensive review of the evidence and from this developed our primary recommendation: Men should get a baseline PSA test in their 40s instead of waiting until their 50s.”
“PSA levels can vary between individuals so a test in the early 40’s can provide a baseline and allow us to better tailor clinical follow-up,” says Prostate Cancer Canada spokesperson Dr. Rajiv Singal, Urologist at Toronto East General Hospital and Assistant Professor at the University of Toronto. “The PSA is an important marker for a disease in which symptoms are not always present.”
PCC also recommends the decision to end PSA testing should be based on individual risk, rather than an arbitrary cut-off such as age 70. “Men are living longer and their lives should not be cut short or diminished by prostate cancer,” says Dr. Edmonds. “The decision to end testing should be a shared decision determined by a man and his primary care provider.”
“Some men are at increased risk because of ethnicity (Black African or Black Caribbean descent), a family history of prostate cancer, or age,” says Dr. Singal. “Men at high risk should talk to their primary care provider even earlier than their 40s. However, in my 18 years of practice, the majority of aggressive cancers have been found in men with seemingly no risk factors – underscoring the importance of baseline testing.”
More from link below
Monday, 21 October 2013
Australia-Prostate Cancer Pack
Please remember the following is from the Prostate Cancer Foundation of Australia but may be
of general interest globally.
Prostate Cancer Foundation of Australia's Localised Prostate Cancer Patient Pack is designed for people with a recent diagnosis of localised prostate cancer. The pack contains a suite of information resources for men and their families and friends.
http://www.prostate.org.au/articleLive/pages/Localised-Prostate-Cancer-Pack.html
UK-PSAwatch In Action!
VIDEOS: Lifesaving Winsford cancer testing event is a UK first
Wednesday 16th October 2013
The testing team at Asda in Winsford
Veteran LHPCSG fundraiser, Winn Bond, process the test in less than ten minutes.
SHOPPERS in Winsford were given the offer of a lifetime courtesy of a royally-recognised cancer testing pioneer.
For the first time ever in the UK, men had the chance to get a lifesaving prostate specific antigen (PSA) test carried out for free while they picked up their weekly groceries.
The Leighton Hospital Prostate Cancer Support Group (LHPCSG) has tested 1,210 men this year alone – successfully treating 38 men for cancer. The charity’s chairman, Gary Steele, was awarded the MBE this year for his lifesaving work, and his tireless campaign to get the Government to roll out his technique across the NHS.
“It’s gone very, very well. There has been a great turnout,” said the Cherry Crescent resident of teh event on Monday, October 7. “Men are coming along, sitting down, and putting their test into the machine. That’s him finished then, and he can go shopping with his misses. “Ten minutes later, he can come back and he’s got his result.
It’s completely revolutionised how we can operate.” The supermarket-based event allowed Gary to target men who might not have found time to attend one of the dedicated testing events he runs throughout the year.
Tony Vine, 68, was visiting his Winsford partner from his home in Rossett in North Wales when he dropped into Asda. In less than 10 minutes he was able to get a PSA test and put his mind at rest. “It was an absolute piece of cake, no problems whatsoever. “I’ve been saying I’d get it done for several years but never got round to it. “It was fantastic walking in today and being able to get it done so quickly.”
http://www.winsfordguardian.co.uk/video/2748009416001/?ref=vidshare
If the PSA test result shows a risk of developing cancer, the charity’s eurologist, Dr David Baxter Smith, conducts another simple test that avoids the need for an invasive biopsy procedure. The sample is then boxed and sent to experts in Cambridge, costing the charity £200.
LHPSSG’s lifesaving work has cost in excess of £40,000 this year alone – all of which has to be raised by charitable donation. “It’s a lot of money, but what price do you put on a man’s life?” said Gary.
http://www.winsfordguardian.co.uk/video/2748009421001/?ref=vidshare
Gary is encouraging men to ‘save a dad; grow a moustache’ next month for ‘Movember’ and raise money for the LHPSSG.
To get in touch for a PSA test or for fundraising forms, call 01606 553097 or email coli.hubball@tiscali.co.uk
For more on prostate cancer, visit prostatecanceruk.org Breakout The UK falls well behind the rest of Europe, and America, in PSA testing. Gary’s work massively expands the current treatments available on the NHS – offering PSA testing to a wider age range, with the offer of further expert testing if required.
In the rest of Europe and throughout many countries elsewhere in the world, all men of 50 are required to undertake a test, and Gary wants to see the UK follow the example, as well as wider use of the life-extending prostate cancer drug, abiraterone.
LHPSSG has detected 51 cancers this year alone, of which 38 have been successfully treated – that’s 38 lives saved. The remainder are on active surveillance, whereby Gary’s charity keeps tabs on the patient, offering further testing and continued support.
80 per cent of men diagnosed with prostate cancer don’t have any symptoms.
Wednesday 16th October 2013
The testing team at Asda in Winsford
Veteran LHPCSG fundraiser, Winn Bond, process the test in less than ten minutes.SHOPPERS in Winsford were given the offer of a lifetime courtesy of a royally-recognised cancer testing pioneer.
For the first time ever in the UK, men had the chance to get a lifesaving prostate specific antigen (PSA) test carried out for free while they picked up their weekly groceries.
The Leighton Hospital Prostate Cancer Support Group (LHPCSG) has tested 1,210 men this year alone – successfully treating 38 men for cancer. The charity’s chairman, Gary Steele, was awarded the MBE this year for his lifesaving work, and his tireless campaign to get the Government to roll out his technique across the NHS.
“It’s gone very, very well. There has been a great turnout,” said the Cherry Crescent resident of teh event on Monday, October 7. “Men are coming along, sitting down, and putting their test into the machine. That’s him finished then, and he can go shopping with his misses. “Ten minutes later, he can come back and he’s got his result.
It’s completely revolutionised how we can operate.” The supermarket-based event allowed Gary to target men who might not have found time to attend one of the dedicated testing events he runs throughout the year.
Tony Vine, 68, was visiting his Winsford partner from his home in Rossett in North Wales when he dropped into Asda. In less than 10 minutes he was able to get a PSA test and put his mind at rest. “It was an absolute piece of cake, no problems whatsoever. “I’ve been saying I’d get it done for several years but never got round to it. “It was fantastic walking in today and being able to get it done so quickly.”
http://www.winsfordguardian.co.uk/video/2748009416001/?ref=vidshare
If the PSA test result shows a risk of developing cancer, the charity’s eurologist, Dr David Baxter Smith, conducts another simple test that avoids the need for an invasive biopsy procedure. The sample is then boxed and sent to experts in Cambridge, costing the charity £200.
LHPSSG’s lifesaving work has cost in excess of £40,000 this year alone – all of which has to be raised by charitable donation. “It’s a lot of money, but what price do you put on a man’s life?” said Gary.
http://www.winsfordguardian.co.uk/video/2748009421001/?ref=vidshare
Gary is encouraging men to ‘save a dad; grow a moustache’ next month for ‘Movember’ and raise money for the LHPSSG.
To get in touch for a PSA test or for fundraising forms, call 01606 553097 or email coli.hubball@tiscali.co.uk
For more on prostate cancer, visit prostatecanceruk.org Breakout The UK falls well behind the rest of Europe, and America, in PSA testing. Gary’s work massively expands the current treatments available on the NHS – offering PSA testing to a wider age range, with the offer of further expert testing if required.
In the rest of Europe and throughout many countries elsewhere in the world, all men of 50 are required to undertake a test, and Gary wants to see the UK follow the example, as well as wider use of the life-extending prostate cancer drug, abiraterone.
LHPSSG has detected 51 cancers this year alone, of which 38 have been successfully treated – that’s 38 lives saved. The remainder are on active surveillance, whereby Gary’s charity keeps tabs on the patient, offering further testing and continued support.
80 per cent of men diagnosed with prostate cancer don’t have any symptoms.
UK-New stat for Black men cancer risk
One in four Black men in UK will get prostate cancer
A shocking new figure released in Black History Month by the health charity Prostate Cancer UK reveals that one in every four Black men in the UK will be diagnosed with prostate cancer at some point in his lifetime*. That’s double the overall 1-in-8 cradle-to-grave risk faced by all men in the UK.
“It’s like Russian Roulette but with only four players chancing the bullet. This statistic is a wake-up call to Black men about the unique danger they face - and we’re warning them to act on it. Fathers, brothers, partners, sons - with every fourth Black man or boy in the UK destined to get this potentially fatal disease at some time, it’s vital that everything possible is done to identify and catch aggressive cancers early”, said Cordwell Thomas, who heads Prostate Cancer UK’s partnership with Britain’s African and African Caribbean communities.
Calculation of the specific lifetime risk to Black men was undertaken by Prostate Cancer UK as part of its continuing drive to support the men of Britain’s two million strong African and African Caribbean population in recognising both the threat to their prostate health and their responsibility to be proactive in seeking out advice and support.
Cordwell Thomas continued:
“Many health professionals are not even aware that Black ancestry is a prostate cancer risk factor. What’s more, Black guys often don’t claim their rights to health care. They’re not first in line to see the GP or to call our helpline to discuss concerns like erectile dysfunction or problems peeing. With so many lives at risk, we all have to work together to ensure that Black men wise up to the issue and those affected seek and receive appropriate healthcare.”
With the backing of its major funding partner, Movember, Prostate Cancer UK provides support to thousands of men facing prostate cancer and it has consistently emphasised the higher risk faced by Black men. The urgent need to help Britain’s Black communities act upon their raised risk means Prostate Cancer UK is bringing together the community leaders and clinicians who can encourage Black men to face up to their heightened prostate cancer risk, engage with it, and take the necessary action.
“It’s your life and the message is know your risk and know your responsibility. It’s about taking charge of your own health. As a Black man, you’re already in a high risk group, so the worst thing to do is to ignore the risk. Confront it, speak to your wife, partner or friends about it, and consult your GP over whether a test is advisable in your case. Even when you have no actual symptoms, you are entitled to a test if you are over 50 and have spoken to your GP”, says Cordwell Thomas.
Football legend, sports broadcaster and ambassador for Prostate Cancer UK, Mark Bright said:
“I’m a black man and I am over 50. My risk of being diagnosed with prostate cancer is significantly higher than that of a white man of the same age. Now we know that one in four black men will be diagnosed with prostate cancer at some time in his life, we owe it to ourselves and our loved ones to take responsibility for our health and understand our risks.
“If you’re a black man and over 50, speak to your GP or call the Prostate Cancer UK helpline to find out about your risk and what you can do about it.”
Prostate Cancer UK volunteer Phil Kissi MBE is a survivor of the disease:
“It is terrifying to think that I could so easily have carried on without knowing anything about prostate cancer despite it being the most common cancer diagnosed in men in the UK. Luckily my GP was very supportive when I raised my concerns with him and I caught the cancer in time to have successful treatment but it saddens me to think that others may not have this chance.
“Ultimately it is up to us men to respect and take responsibility for our health but I needed a lot of support from my friends and family,” he says.
“2013 is the 65th anniversary of the Windrush Landing. It is ironical that youngsters who arrived on that ship a whole lifetime ago and have won countless battles over the decades still face a major public health inequality based on nothing but ethnicity. That’s why Prostate Cancer UK puts in the research, services and support that will help more Black men like Phil to survive this disease,” said Cordwell Thomas.
If you have concerns about prostate cancer or the raised risk to men of black ancestry please call Prostate Cancer UK's confidential Helpline on 0800 074 8383 or visit www.prostatecanceruk.org. The helpline is free to landlines, staffed by specialist nurses, and open from 9am to 6pm Monday to Friday with late opening until 8pm on Wednesdays.
A shocking new figure released in Black History Month by the health charity Prostate Cancer UK reveals that one in every four Black men in the UK will be diagnosed with prostate cancer at some point in his lifetime*. That’s double the overall 1-in-8 cradle-to-grave risk faced by all men in the UK.
“It’s like Russian Roulette but with only four players chancing the bullet. This statistic is a wake-up call to Black men about the unique danger they face - and we’re warning them to act on it. Fathers, brothers, partners, sons - with every fourth Black man or boy in the UK destined to get this potentially fatal disease at some time, it’s vital that everything possible is done to identify and catch aggressive cancers early”, said Cordwell Thomas, who heads Prostate Cancer UK’s partnership with Britain’s African and African Caribbean communities.
Calculation of the specific lifetime risk to Black men was undertaken by Prostate Cancer UK as part of its continuing drive to support the men of Britain’s two million strong African and African Caribbean population in recognising both the threat to their prostate health and their responsibility to be proactive in seeking out advice and support.
Cordwell Thomas continued:
“Many health professionals are not even aware that Black ancestry is a prostate cancer risk factor. What’s more, Black guys often don’t claim their rights to health care. They’re not first in line to see the GP or to call our helpline to discuss concerns like erectile dysfunction or problems peeing. With so many lives at risk, we all have to work together to ensure that Black men wise up to the issue and those affected seek and receive appropriate healthcare.”
With the backing of its major funding partner, Movember, Prostate Cancer UK provides support to thousands of men facing prostate cancer and it has consistently emphasised the higher risk faced by Black men. The urgent need to help Britain’s Black communities act upon their raised risk means Prostate Cancer UK is bringing together the community leaders and clinicians who can encourage Black men to face up to their heightened prostate cancer risk, engage with it, and take the necessary action.
“It’s your life and the message is know your risk and know your responsibility. It’s about taking charge of your own health. As a Black man, you’re already in a high risk group, so the worst thing to do is to ignore the risk. Confront it, speak to your wife, partner or friends about it, and consult your GP over whether a test is advisable in your case. Even when you have no actual symptoms, you are entitled to a test if you are over 50 and have spoken to your GP”, says Cordwell Thomas.
Football legend, sports broadcaster and ambassador for Prostate Cancer UK, Mark Bright said:
“I’m a black man and I am over 50. My risk of being diagnosed with prostate cancer is significantly higher than that of a white man of the same age. Now we know that one in four black men will be diagnosed with prostate cancer at some time in his life, we owe it to ourselves and our loved ones to take responsibility for our health and understand our risks.
“If you’re a black man and over 50, speak to your GP or call the Prostate Cancer UK helpline to find out about your risk and what you can do about it.”
Prostate Cancer UK volunteer Phil Kissi MBE is a survivor of the disease:
“It is terrifying to think that I could so easily have carried on without knowing anything about prostate cancer despite it being the most common cancer diagnosed in men in the UK. Luckily my GP was very supportive when I raised my concerns with him and I caught the cancer in time to have successful treatment but it saddens me to think that others may not have this chance.
“Ultimately it is up to us men to respect and take responsibility for our health but I needed a lot of support from my friends and family,” he says.
“2013 is the 65th anniversary of the Windrush Landing. It is ironical that youngsters who arrived on that ship a whole lifetime ago and have won countless battles over the decades still face a major public health inequality based on nothing but ethnicity. That’s why Prostate Cancer UK puts in the research, services and support that will help more Black men like Phil to survive this disease,” said Cordwell Thomas.
If you have concerns about prostate cancer or the raised risk to men of black ancestry please call Prostate Cancer UK's confidential Helpline on 0800 074 8383 or visit www.prostatecanceruk.org. The helpline is free to landlines, staffed by specialist nurses, and open from 9am to 6pm Monday to Friday with late opening until 8pm on Wednesdays.
Saturday, 19 October 2013
Initial Approach from Laborie Medical
Oct 18 (Reuters) - Mediwatch PLC : * Response to increase in share price * Mediwatch confirms that it has received an initial approach from laborie
Monday, 14 October 2013
LATEST NEWS AND FUTURE EVENTS
Latest News/Website Updates
Oct 18 (Reuters) - Mediwatch PLC : * Response to increase in share price * Mediwatch confirms that it has received an initial approach from laborie
Mediwatch Positions/Jobs
Future Events Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later
University of Minnesota Colon & Rectal surgery meeting in Minneapolis to demonstrate our newest products.(Wednesday | Oct 23, 2013-date is a guess! )
AUGS 34th Annual Scientific Meeting
October 16-19, 2013
Location: Caesars Palace, Las Vegas, NV
2013 Annual ConferenceOctober 11-14, 2013
Hyatt Regency
Chicago, IL
Mediwatch/Distributor Training Courses
Urodynamics Workshop WPB--- 23,24 Mar 2013
ARM Workshop Boston 31 May 2013
Urodynamics Workshop WPB 9,10 Nov 2013
Newsletters
Mediwatch Newsletter 2013 Q3
Mediwatch Newsletter 2013 Q2
Mediwatch Newsletter 2012 Q1
Mediwatch Newsletter 2011 Q4
STUFF THAT MAYBE DID BUT NOW DOESN'T FIT IN WITH THE TITLE...
Saturday, 7 September 2013
Canada-New screening guidelines PC
New screening guidelines for prostate cancer recommend that men first be tested when in their 40s in order to establish a "baseline" for future risk.
The guidelines -- released by Prostate Cancer Canada on Wednesday -- suggest men should receive an initial Prostate-specific Antigen (PSA) blood test in their 40s so they "know their numbers" earlier.
A PSA test is the standard screening test for prostate cancer, though elevated levels of PSA in the blood can be caused by a number of factors -- and is not necessarily linked to prostate cancer.
It was previously suggested that men could wait until their 50s to take a PSA test.
Prostate Cancer Canada also suggests that the decision to end PSA testing should be based on individual risk, rather than an "arbitrary" cut-off age, such as 70.
The guidelines were released after a nation-wide poll that showed, while 87 per cent of Canadian men over the age of 34 fear prostate cancer, less than 50 per cent anticipate being tested in the next 12 months.
Prostate cancer is the most common form of cancer affecting Canadian men, with approximately one-in-seven being impacted by it over the course of their life.
Dr. Stuart Edmonds, vice-president of research and health promotion at Prostate Cancer Canada, said that men need to be better informed about prostate testing. The new guidelines are the result of an extensive review of the research and evidence, he added.
Prostate Cancer Canada spokesperson and assistant professor of surgery Dr. Rajiv Singal said getting a PSA test in your early 40s can provide a better baseline and later allow doctors to better tailor a clinical follow-up.
"The PSA is an important marker for a disease in which symptoms are not always present," he said in a statement.
Prostate Cancer Canada President Rocco Rossi told CTV's Canada AM that men who are at greater risk for prostate cancer -- including men of African or Caribbean descent or men who have a history of prostate cancer in their family -- should speak with their doctors about getting tested in their 30s.
"All the research shows us that with early detection prostate cancer is treatable in over 90 per cent of the cases. So if you wait too late, you lose the benefit of that early detection," he said.
He stressed that getting a PSA test in your 40s does not automatically mean yearly testing or treatment. Instead, it's about "establishing a baseline."
Rossi compared getting a PSA test to getting your cholesterol checked. "This is one of those numbers that you need to know."
He acknowledged concerns that earlier screening may lead to over-diagnosis and possible unnecessary biopsies, but said that decision lies with the physician.
"We want to avoid that and that's the responsibility of the doctor and the urologist to go through a proper triaging … a proper escalation," Rossi said.
After knowing the results of your PSA test, patients can consult with their doctors and determine the next course of action, including setting up a testing routine that's appropriate for a patient's individual risk level, he added.
Risk of over treating
But with more screening there is always the concern of over treating, says CTV's Medical Expert Dr. Marla Shapiro.
"When we talk about doing a screening test, it's not just the result of the screening test it's what that screening test leads to," Shapiro said Wednesday.
And with prostate cancer screening there is the chance of it leading to a biopsy, which carries risks including infection, sepsis, fever and hemorrhage, she said.
"We want to make sure we're introducing a test where the downside is not going to blur out the potential diagnostic benefit.”
She noted that a good screening test should have the ability to separate high cancer burden that will end up developing into a significant outcome versus cases that might never develop.
She added that guidelines on prostate cancer screening vary across North America which can lead to confusion for patients.
For example, the U.S. Preventative Task Force recommends no one be screened with a PSA test because it doesn't actually show a survival benefit.
Meanwhile the American Urological Association recommends PSA testing between the ages of 55 to 69 and only earlier for special high-risk groups.
Memorial Sloan-Kettering Cancer Center in the U.S. recommends testing between the ages of 45 to 49 for individuals of average risk and additional screening to be determined based on the results of the initial test.
Shapiro said the different recommendations show the need for more education for men so they can speak with their doctor about the best screening options for them.
"I think it's very hard to have these broad screening guidelines," she said. "What this means is that you as an individual man have to have the conversation with your physician and understand the entire implications of what this means to have a PSA, how frequently it should be done and the possible outcomes it could lead to."
The guidelines -- released by Prostate Cancer Canada on Wednesday -- suggest men should receive an initial Prostate-specific Antigen (PSA) blood test in their 40s so they "know their numbers" earlier.
A PSA test is the standard screening test for prostate cancer, though elevated levels of PSA in the blood can be caused by a number of factors -- and is not necessarily linked to prostate cancer.
It was previously suggested that men could wait until their 50s to take a PSA test.
Prostate Cancer Canada also suggests that the decision to end PSA testing should be based on individual risk, rather than an "arbitrary" cut-off age, such as 70.
The guidelines were released after a nation-wide poll that showed, while 87 per cent of Canadian men over the age of 34 fear prostate cancer, less than 50 per cent anticipate being tested in the next 12 months.
Prostate cancer is the most common form of cancer affecting Canadian men, with approximately one-in-seven being impacted by it over the course of their life.
Dr. Stuart Edmonds, vice-president of research and health promotion at Prostate Cancer Canada, said that men need to be better informed about prostate testing. The new guidelines are the result of an extensive review of the research and evidence, he added.
Prostate Cancer Canada spokesperson and assistant professor of surgery Dr. Rajiv Singal said getting a PSA test in your early 40s can provide a better baseline and later allow doctors to better tailor a clinical follow-up.
"The PSA is an important marker for a disease in which symptoms are not always present," he said in a statement.
Prostate Cancer Canada President Rocco Rossi told CTV's Canada AM that men who are at greater risk for prostate cancer -- including men of African or Caribbean descent or men who have a history of prostate cancer in their family -- should speak with their doctors about getting tested in their 30s.
"All the research shows us that with early detection prostate cancer is treatable in over 90 per cent of the cases. So if you wait too late, you lose the benefit of that early detection," he said.
He stressed that getting a PSA test in your 40s does not automatically mean yearly testing or treatment. Instead, it's about "establishing a baseline."
Rossi compared getting a PSA test to getting your cholesterol checked. "This is one of those numbers that you need to know."
He acknowledged concerns that earlier screening may lead to over-diagnosis and possible unnecessary biopsies, but said that decision lies with the physician.
"We want to avoid that and that's the responsibility of the doctor and the urologist to go through a proper triaging … a proper escalation," Rossi said.
After knowing the results of your PSA test, patients can consult with their doctors and determine the next course of action, including setting up a testing routine that's appropriate for a patient's individual risk level, he added.
Risk of over treating
But with more screening there is always the concern of over treating, says CTV's Medical Expert Dr. Marla Shapiro.
"When we talk about doing a screening test, it's not just the result of the screening test it's what that screening test leads to," Shapiro said Wednesday.
And with prostate cancer screening there is the chance of it leading to a biopsy, which carries risks including infection, sepsis, fever and hemorrhage, she said.
"We want to make sure we're introducing a test where the downside is not going to blur out the potential diagnostic benefit.”
She noted that a good screening test should have the ability to separate high cancer burden that will end up developing into a significant outcome versus cases that might never develop.
She added that guidelines on prostate cancer screening vary across North America which can lead to confusion for patients.
For example, the U.S. Preventative Task Force recommends no one be screened with a PSA test because it doesn't actually show a survival benefit.
Meanwhile the American Urological Association recommends PSA testing between the ages of 55 to 69 and only earlier for special high-risk groups.
Memorial Sloan-Kettering Cancer Center in the U.S. recommends testing between the ages of 45 to 49 for individuals of average risk and additional screening to be determined based on the results of the initial test.
Shapiro said the different recommendations show the need for more education for men so they can speak with their doctor about the best screening options for them.
"I think it's very hard to have these broad screening guidelines," she said. "What this means is that you as an individual man have to have the conversation with your physician and understand the entire implications of what this means to have a PSA, how frequently it should be done and the possible outcomes it could lead to."
Tuesday, 3 September 2013
Blue September
Blue September is a nationwide awareness and fundraising initiative about all the cancers that affect men – not just prostate and testicular cancer, but also bowel, lung, liver, pancreatic and other cancers. The campaign aims to raise funds for Australian Prostate Cancer Research and Australian Cancer Research Foundation charities to raise men's awareness of cancer and help them to reduce the risk of developing and dying from cancer by making better lifestyle choices and seeking help sooner rather than later.
LATEST NEWS AND FUTURE EVENTS
Latest News/Website Updates
Mediwatch Positions/Jobs
Future Events Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later
Mediwatch/Distributor Training Courses
Urodynamics Workshop WPB--- 23,24 Mar 2013
ARM Workshop Boston 31 May 2013
Urodynamics Workshop WPB 9,10 Nov 2013
Newsletters
Mediwatch Newsletter 2013 Q2
Mediwatch Newsletter 2012 Q1
Mediwatch Newsletter 2011 Q4
STUFF THAT MAYBE DID BUT NOW DOESN'T FIT IN WITH THE TITLE...
Sunday, 18 August 2013
UK-PCaSO Prostate Cancer Network
Below is a link to the latest PCaSO Prostate Cancer Network newsletter:
New, six-point statement about PSA testing issued at PCWC
This was posted on 'The New Prostate Cancer InfoLink' on the 7th August:
Posted on August 7, 2013 by Sitemaster
According to a report on the Bloomberg.com web site, attendees meeting at the Prostate Cancer World Congress (PCWC) in Melbourne, Australia have issued a new, six-point consensus statement about the use of the PSA test in the initial detection of prostate cancer.
The key points of the consensus statement are as follows:
•For men aged 50–69, there is evidence that PSA testing reduces the risk of metastatic prostate cancer and of death from prostate cancer by up to 30 percent and 21 percent, respectively.
•Prostate cancer diagnosis must be uncoupled from prostate cancer intervention through active surveillance of men with low-volume, low-risk prostate cancer.
•PSA testing should not be considered on its own but as part of a multivariable approach, including digital rectal examination, prostate volume, family history, ethnicity, and risk prediction models.
•Baseline PSA testing for men in their 40s is useful for predicting the future risk of prostate cancer, especially for those whose baseline PSA is in the highest centiles above the median
•Older men in good health with a life expectancy of more than 10 years should not be denied PSA testing on the basis of their age because a small proportion of older men may benefit from an early diagnosis of more aggressive forms of localized prostate cancer.
The “New” Prostate Cancer InfoLink concurs completely with this six-point statement. The critical issue will be whether the global urology community actually starts to act in accordance with these six points and proactively starts to help patients with clinically insignificant prostate cancer to avoid over-treatment and its consequences.
http://prostatecancerinfolink.net/2013/08/07/new-six-point-statement-about-psa-testing-issued-at-pcwc/
Posted on August 7, 2013 by Sitemaster
According to a report on the Bloomberg.com web site, attendees meeting at the Prostate Cancer World Congress (PCWC) in Melbourne, Australia have issued a new, six-point consensus statement about the use of the PSA test in the initial detection of prostate cancer.
The key points of the consensus statement are as follows:
•For men aged 50–69, there is evidence that PSA testing reduces the risk of metastatic prostate cancer and of death from prostate cancer by up to 30 percent and 21 percent, respectively.
•Prostate cancer diagnosis must be uncoupled from prostate cancer intervention through active surveillance of men with low-volume, low-risk prostate cancer.
•PSA testing should not be considered on its own but as part of a multivariable approach, including digital rectal examination, prostate volume, family history, ethnicity, and risk prediction models.
•Baseline PSA testing for men in their 40s is useful for predicting the future risk of prostate cancer, especially for those whose baseline PSA is in the highest centiles above the median
•Older men in good health with a life expectancy of more than 10 years should not be denied PSA testing on the basis of their age because a small proportion of older men may benefit from an early diagnosis of more aggressive forms of localized prostate cancer.
The “New” Prostate Cancer InfoLink concurs completely with this six-point statement. The critical issue will be whether the global urology community actually starts to act in accordance with these six points and proactively starts to help patients with clinically insignificant prostate cancer to avoid over-treatment and its consequences.
http://prostatecancerinfolink.net/2013/08/07/new-six-point-statement-about-psa-testing-issued-at-pcwc/
Friday, 16 August 2013
UK-Graham Fulford Charitable Trust
Newsletter from the Graham Fulford Charitable Trust entitled Our First Nine Years!
And a link to their website:
And a link to their website:
Subscribe to:
Posts (Atom)